Treatment with an anti-programmed death-ligand 1 (PD-L1) antibody has demonstrated a significant reduction of CD163+ macrophage infiltration in glioma, implying a potential relationship between CD163 expression and immune checkpoint mechanisms [171]. This evidence concerns the gene CD163 and central nervous system cancer.